| abstract |
The present disclosure relates to a stable formulation of a receptor tyrosine kinase inhibitor (TKI), eg, pazopanib; a method for its preparation; and the use of the disclosed formulation in sustained delivery of the active agent to a target site. The present disclosure further relates to a method of converting one polymorphic form of TKI to another polymorphic and / or amorphous form. |